<html xmlns="http://www.w3.org/1999/xhtml"><body><table style="border: 1px solid black;"><caption /><tr><th style="border: 1px solid black;">Study type (CONSORT/STROBE) </th><th style="border: 1px solid black;">Main cancer class </th><th style="border: 1px solid black;">CIPN severity report (count by grade if given) </th><th style="border: 1px solid black;">CIPN assessment time points </th><th style="border: 1px solid black;">CIPN assessment method(s) </th></tr><tr><td style="border: 1px solid black;">Oxaliplatin: 72.3% (95% CI = 59.7–86.8)</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">NR</td><td style="border: 1px solid black;">Unclear</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Antonacopoulou</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade I (6/16)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade II (8/16)</td><td style="border: 1px solid black;">Cycles 4, 8, 12</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">(2009) ^{*}</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade III (2/16)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Argyriou (2007) [8]</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade I (38/125)</td><td style="border: 1px solid black;">Cycles 3, 6 (FOLFOX)</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade II (46/125)</td><td style="border: 1px solid black;">Cycles 4, 8 (XELOX)</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Argyriou (2012)</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade III (41/125)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade I (62/169)</td><td style="border: 1px solid black;">Cycle 6, 12 (FOLFOX)</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Argyriou (2013) ^{†}</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade II (46/169)</td><td style="border: 1px solid black;">Cycles 4, 8 (XELOX)</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Grade III (61/169)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Attal (2009)</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">Sensory symptom counts</td><td style="border: 1px solid black;">Cycle 3, 6, 9</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Colorectal</td><td style="border: 1px solid black;">described as means/</td><td style="border: 1px solid black;">12 ± 2 mo after chemo end</td><td style="border: 1px solid black;">(EORTC) QLQ-C30</td></tr><tr><td style="border: 1px solid black;">Cascinu (2002)</td><td style="border: 1px solid black;">Lung</td><td style="border: 1px solid black;">individual</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">Gastrointestinal</td><td style="border: 1px solid black;">Grade I (4/15)</td><td style="border: 1px solid black;">Cycles 4, 8, 12</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Gobran (2013)</td><td style="border: 1px solid black;">Ovarian and</td><td style="border: 1px solid black;">Grade II (6/15)</td><td style="border: 1px solid black;">Within 2 wk of chemo end</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">lung</td><td style="border: 1px solid black;">Grade III (4/15)</td><td style="border: 1px solid black;">Unclear if at baseline</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Ishibashi (2010)</td><td style="border: 1px solid black;">Gynecological</td><td style="border: 1px solid black;">Grade IV (1/15)</td><td style="border: 1px solid black;">At each chemo cycle until end of chemo</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">Multiple solid</td><td style="border: 1px solid black;">Grade I (7/21)</td><td style="border: 1px solid black;">(variable no. of cycles)</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Krishnan (2005)</td><td style="border: 1px solid black;">Multiple solid</td><td style="border: 1px solid black;">Grade II (0/21)</td><td style="border: 1px solid black;">Longer follow-up for those with CIPN (but</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Multiple solid</td><td style="border: 1px solid black;">Grade III (14/21)</td><td style="border: 1px solid black;">denominator unclear)</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Lin (2006)</td><td style="border: 1px solid black;">Gynecological</td><td style="border: 1px solid black;">Grade IV (0/21)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Controlled trial</td><td style="border: 1px solid black;">Grade I (15/15)</td><td style="border: 1px solid black;">At each chemo cycle until end of chemo</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Milla (2009)</td><td style="border: 1px solid black;">Grade II (1/15)</td><td style="border: 1px solid black;">No baseline</td><td style="border: 1px solid black;">NES</td></tr><tr><td style="border: 1px solid black;">Controlled trial</td><td style="border: 1px solid black;">Grade III (0/15)</td><td style="border: 1px solid black;">Within 1 mo of chemo end only reported</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Won (2012)</td><td style="border: 1px solid black;">Grade IV (0/15)</td><td style="border: 1px solid black;">assessment</td><td style="border: 1px solid black;">NES</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">NR</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">PNS</td></tr><tr><td style="border: 1px solid black;">Cisplatin: 42.2% (95% CI = 21.3–63.1)</td><td style="border: 1px solid black;">Grade I (1/9)</td><td style="border: 1px solid black;">Cycles 4, 8, 12</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Argyriou (2006) ^{‡}</td><td style="border: 1px solid black;">Grade II (5/9)</td><td style="border: 1px solid black;">Within 2 wk of end of chemo</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">Grade III (3/9)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Cascinu (1995)</td><td style="border: 1px solid black;">Grade IV (0/9)</td><td style="border: 1px solid black;">Cycles 5, 9, 12</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">Grade I (0/13)</td><td style="border: 1px solid black;">(Some followed up longer but denominator</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Gandara (1995)</td><td style="border: 1px solid black;">Grade II (9/13)</td><td style="border: 1px solid black;">unclear)</td><td style="border: 1px solid black;">NES</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">Grade III (4/13)</td><td style="border: 1px solid black;">Unclear if at baseline</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Kemp (1996)</td><td style="border: 1px solid black;">NR</td><td style="border: 1px solid black;">At each chemo cycle until end of chemo</td><td style="border: 1px solid black;">NES</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">Reported by age group</td><td style="border: 1px solid black;">(variable no. of cycles)</td><td style="border: 1px solid black;">TNSc</td></tr><tr><td style="border: 1px solid black;">Pace (2003)</td><td style="border: 1px solid black;">only</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NPS</td></tr><tr><td style="border: 1px solid black;">Controlled trial</td><td style="border: 1px solid black;">Grade I (3/16)</td><td style="border: 1px solid black;">Cycles 3, 6</td><td style="border: 1px solid black;">NCI-CTC</td></tr><tr><td style="border: 1px solid black;">Pace (2010)</td><td style="border: 1px solid black;">Grade II (10/16)</td><td style="border: 1px solid black;">3 mo after chemo end</td><td style="border: 1px solid black;">NES</td></tr><tr><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">Grade III (2/16)</td><td style="border: 1px solid black;">Baseline</td><td style="border: 1px solid black;">NES</td></tr><tr><td style="border: 1px solid black;">Planting (1999)</td><td style="border: 1px solid black;">Grade IV (1/16)</td><td style="border: 1px solid black;">After 9 and 15 wk of therapy</td></tr><tr><td style="border: 1px solid black;">Controlled trial</td><td style="border: 1px solid black;">Only grade P3 reported</td><td style="border: 1px solid black;">Within 1 wk after end of chemo</td></tr><tr><td style="border: 1px solid black;">Van der Hoop (1999)</td><td style="border: 1px solid black;">Grade I (31/81)</td><td style="border: 1px solid black;">Unclear if at baseline</td></tr><tr><td style="border: 1px solid black;">Controlled trial</td><td style="border: 1px solid black;">Grade II (35/81)</td><td style="border: 1px solid black;">At each cycle until chemo end (variable no. of</td></tr></table></body></html>